Cargando…

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as a promising non-invasive biomarker in clinical oncology. Analysis of ctDNA opens up new avenues for individualized cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Yan, Mei, Wuxuan, Ma, Kaidong, Zeng, Changchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637327/ https://www.ncbi.nlm.nih.gov/pubmed/34868984 http://dx.doi.org/10.3389/fonc.2021.763790

Ejemplares similares

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
por: Zhu, Lemei, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021)

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer
por: Fang, Xiaoxu, et al.
Publicado: (2022)

Circulating Tumor Cells in Gastrointestinal Cancers: Current Status and Future Perspectives
por: Yang, Chaogang, et al.
Publicado: (2019)

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
por: Peng, Yan, et al.
Publicado: (2022)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer
por: Jiang, Jiahong, et al.
Publicado: (2020)

Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma
por: Liu, Tao, et al.
Publicado: (2021)

Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches
por: Kostopoulos, Ioannis V., et al.
Publicado: (2020)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Circulating Tumor Cells: Back to the Future
por: Gallerani, Giulia, et al.
Publicado: (2017)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA
por: Ottaviano, Margaret, et al.
Publicado: (2021)

Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives
por: Sun, Hongna, et al.
Publicado: (2022)

Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers – current evidence and future directions
por: Lam, Rachel C. T., et al.
Publicado: (2022)

Tumor-Educated Platelets: A Review of Current and Potential Applications in Solid Tumors
por: Varkey, Joyce, et al.
Publicado: (2021)

SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?
por: Turcas, Cristina, et al.
Publicado: (2020)

Tumor microenvironment penetrating chitosan nanoparticles for elimination of cancer relapse and minimal residual disease
por: Mahmudi, Hossein, et al.
Publicado: (2022)

Plasma-only circulating tumor DNA analysis detects minimal residual disease and predicts early relapse in hepatocellular carcinoma patients undergoing curative resection
por: Xu, Yuyan, et al.
Publicado: (2023)

Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives
por: Lu, Chang, et al.
Publicado: (2022)

Circulating Tumor Cells in Desmoid Tumors: New Perspectives
por: Braun, Alexcia C., et al.
Publicado: (2021)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Minimal residual disease and circulating tumor cells in breast cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Sarcoma Metabolomics: Current Horizons and Future Perspectives
por: Esperança-Martins, Miguel, et al.
Publicado: (2021)

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
por: Nagafuji, Koji, et al.
Publicado: (2013)

A Cost Impact Analysis of clonoSEQ(®) as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
por: Walzer, Stefan, et al.
Publicado: (2021)

Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review)
por: Chen, Huijuan, et al.
Publicado: (2023)

Minimal residual disease (MRD) in the bone marrow in ER-α-positive primary breast cancer patients
por: Coombes, RC, et al.
Publicado: (2005)

Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
por: Prisciandaro, Michele, et al.
Publicado: (2022)

Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective
por: Li, Ying, et al.
Publicado: (2023)

Analysis of Subset Chimerism for MRD-Detection and Pre-Emptive Treatment in AML
por: Georgi, Julia-Annabell, et al.
Publicado: (2022)

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice
por: Turner, Rose, et al.
Publicado: (2022)

Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?
por: Guolo, Fabio, et al.
Publicado: (2022)

Tumor DNA From Tumor In Situ Fluid Reveals Mutation Landscape of Minimal Residual Disease After Glioma Surgery and Risk of Early Recurrence
por: Yu, Jinliang, et al.
Publicado: (2021)

Atypical Teratoid Rhabdoid Tumor: Current Therapy and Future Directions
por: Ginn, Kevin F., et al.
Publicado: (2012)

Current therapies and future prospective for locally aggressive mesenchymal tumors
por: Maleddu, Alessandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_na03jcr6n949rv03fs6pdubs58